Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte is a clinical-stage biotech company that has a strong pipeline of potential vaccine candidates addressing unmet needs in adult and pediatric indications with high market opportunities. With positive Phase 1/2 data and fast-track designation for their lead candidate VAX-24 for pneumococcal disease, as well as updates on their other vaccine programs, the company is on track for pivotal Phase 3 data in 2026. This, along with their established financial backing, makes Vaxcyte a top pick for 2026 with a potentially transformational 18 months ahead, positioning their stock for growth in the years to come.

Bears say

Vaxcyte is a clinical-stage vaccine company with a strong product pipeline, including VAX-31, VAX-24, VAX-XL, VAX-A1, and VAX-GI. However, the company may face challenges in bringing these vaccines to market, with the earliest potential market entry not expected until 2027 and projected peak penetration of 60% in newborns. Additionally, there are uncertainties around pricing and potential serotype replacement. These factors lead to a negative outlook for Vaxcyte's stock and a valuation primarily relying on VAX-24 with a discounted cash flow analysis assuming a 14.5% discount rate and 1.0% terminal growth rate.

Vaxcyte (PCVX) has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Buy based on their latest research and market trends.

According to 4 analysts, Vaxcyte (PCVX) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.